Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 100
Filter
1.
Comput Math Methods Med ; 2021: 8746264, 2021.
Article in English | MEDLINE | ID: mdl-34925546

ABSTRACT

OBJECTIVE: To investigate the quantity of CD4+T, CD4+T, CD8+T, and γδT cells in peripheral blood of HIV-infected/AIDS patients as well as to explore the possible role of CD4/CD8 ratio and γδT cells in the progression of HIV/AIDS, aimed at providing evidence for the diagnosis and treatment of AIDS. METHODS: The quantity levels of CD3+T cells, CD4+T cells, CD8+T cells, and γδT cells in peripheral blood of 46 HIV-infected/AIDS patients and 30 healthy controls were detected by using flow cytometry. RESULTS: The count of CD3+T, CD4+T, CD8+T, and γδT cells ( x ¯ ± s , A/µl) in the peripheral blood was 1183.64 ± 132.58, 278.39 ± 122.38, 863.13 ± 82.38, and 22.53 ± 1.74 in the experimental group as well as 1456.46 ± 124.37, 788.74 ± 189.67, 569.61 ± 46.49, and 10.96 ± 0.28 in the control group, respectively. The p values of the two groups were <0.005 after the t-test, revealing a statistically significant difference. The proportion of CD3+T, CD4+T, CD8+T, and γδT cells in total lymphocytes in the two groups ( x ¯ ± s , %) was 71.83 ± 5.37, 13.39 ± 2.23, 62.93 ± 5.81, and 3.67 ± 0.87 in the experimental group, respectively. In the control group, the values were expressed as 66.72 ± 5.48, 42.77 ± 3.38, 31.41 ± 3.62, and 1.73 ± 0.36, respectively. After performing the t-test, p values in the two groups were <0.005 except CD3+T, with statistically significant differences. Besides, CD4/CD8 was 0.33 ± 0.11 in the experimental group and 1.48 ± 0.29 in the control group, t = 26.528, p < 0.001, exhibiting a significant statistical difference. CONCLUSION: HIV infection induces the activation and proliferation of CD8+T and γδT cells, contributing to the decrease of CD4+T cells, while CD8+T and γδT cells are involved in the immune response and tissue damage after HIV infection.


Subject(s)
Acquired Immunodeficiency Syndrome/immunology , HIV Infections/immunology , T-Lymphocyte Subsets/classification , T-Lymphocyte Subsets/immunology , Acquired Immunodeficiency Syndrome/blood , Adult , Aged , CD3 Complex/blood , CD4 Lymphocyte Count , CD4-CD8 Ratio , Case-Control Studies , Cell Proliferation , Computational Biology , Female , HIV Infections/blood , Humans , Lymphocyte Activation , Lymphocyte Count , Male , Middle Aged , Receptors, Antigen, T-Cell, gamma-delta/blood , Young Adult
2.
J Neuroimmunol ; 356: 577597, 2021 07 15.
Article in English | MEDLINE | ID: mdl-33964735

ABSTRACT

We enumerated conventional and innate lymphocyte populations in neonates with neonatal encephalopathy (NE), school-age children post-NE, children with cerebral palsy and age-matched controls. Using flow cytometry, we demonstrate alterations in circulating T, B and natural killer cell numbers. Invariant natural killer T cell and Vδ2+ γδ T cell numbers and frequencies were strikingly higher in neonates with NE, children post-NE and children with cerebral palsy compared to age-matched controls, whereas mucosal-associated invariant T cells and Vδ1 T cells were depleted from children with cerebral palsy. Upon stimulation ex vivo, T cells, natural killer cells and Vδ2 T cells from neonates with NE more readily produced inflammatory cytokines than their counterparts from healthy neonates, suggesting that they were previously primed or activated. Thus, innate and conventional lymphocytes are numerically and functionally altered in neonates with NE and these changes may persist into school-age.


Subject(s)
Brain Diseases/blood , Brain Diseases/diagnosis , Cerebral Palsy/blood , Cerebral Palsy/diagnosis , Natural Killer T-Cells/metabolism , Receptors, Antigen, T-Cell, gamma-delta/blood , Brain Diseases/immunology , Cerebral Palsy/immunology , Child , Female , Follow-Up Studies , Humans , Infant, Newborn , Male , Natural Killer T-Cells/immunology , Receptors, Antigen, T-Cell, gamma-delta/immunology , Students , T-Lymphocyte Subsets/immunology , T-Lymphocyte Subsets/metabolism
3.
PLoS One ; 15(6): e0235162, 2020.
Article in English | MEDLINE | ID: mdl-32584913

ABSTRACT

BACKGROUND: Preterm birth is the leading cause of neonatal and child mortality worldwide. Maternal HIV infection and antiretroviral treatment (ART) increase the rate of preterm birth, but the underlying mechanisms remain unknown, limiting progress in prediction, prevention and treatment. While overall γδ T cell levels remain constant, acute HIV infection is associated with a depletion of the Vδ2 subset and an increase in the Vδ1 subset, which do not return to baseline with ART. γδ T cells have also been implicated in adverse pregnancy outcomes and we therefore investigated the potential association between maternal HIV infection, peripheral γδ T cell frequencies and preterm birth. METHODS: Study participants were HIV positive (n = 47) and HIV negative (n = 45) women enrolled in a prospective pregnancy cohort study at Chris Hani Baragwanath Academic Hospital in Soweto, South Africa. Women were enrolled in early pregnancy and gestational age was accurately determined by first trimester ultrasound scan. Peripheral blood samples were collected in each trimester and peripheral blood mononuclear cells isolated. Frequencies of γδ T cells, Vδ1+ and Vδ2+ γδ T cell subsets, and CCR6 chemokine receptor expression were determined by flow cytometry. RESULTS: Total γδ T cell levels were similar between HIV positive and HIV negative women throughout pregnancy. However, in each trimester maternal HIV infection was associated with reduced levels of the Vδ2+ subset and increased levels of the Vδ1+ subset, leading to a reversal of the Vδ1/Vδ2 ratio. Timing of ART initiation among HIV positive women did not affect levels of γδ T cells, the Vδ1+ and Vδ2+ subsets, or the Vδ1/Vδ2 ratio. Importantly, preterm birth was associated with lower total γδ T cell levels in early pregnancy and γδ T cell frequencies were lowest in HIV positive women who delivered preterm. Moreover, in the first trimester the proportion of Vδ1+ T cells that were CCR6+ was significantly reduced in HIV+ women and women who delivered preterm, resulting in the lowest proportion of CCR6+ Vδ1 T cells in HIV positive women who delivered preterm. CONCLUSIONS: Our findings suggest that altered γδ T cell frequencies may link maternal HIV infection and preterm birth. γδ T cell frequencies in early pregnancy may serve as predictive biomarkers to identify women at risk of delivering preterm.


Subject(s)
HIV Infections/blood , HIV-1 , Premature Birth/blood , Receptors, Antigen, T-Cell, gamma-delta/blood , T-Lymphocytes/metabolism , Adult , Biomarkers/blood , Female , Flow Cytometry , HIV Infections/drug therapy , Humans , Immunosuppression Therapy , Pregnancy , Pregnancy Complications, Infectious , Receptors, CCR6/blood , South Africa
4.
Front Immunol ; 11: 12, 2020.
Article in English | MEDLINE | ID: mdl-32117220

ABSTRACT

The immune system contributes to neurodegenerative pathologies. However, the roles of γδ T cells in Alzheimer's disease (AD) are poorly understood. Here, we evaluated somatic variability of T-cell receptor γ genes (TRGs) in patients with AD. We performed deep sequencing of the CDR3 region of TRGs in patients with AD and control patients without dementia. TRG clones were clearly detectable in peripheral blood (PB) and non-neuronal cell populations in human brains. TRG repertoire diversity was reduced during aging. Compared with the PB, the brain showed reduced TRGV9 clonotypes but was enriched in TRGV2/4/8 clonotypes. AD-associated TRG profiles were found in both the PB and brain. Moreover, some groups of clonotypes were more specific for the brain or blood in patients with AD compared to those in controls. Our pilot deep analysis of T-cell receptor diversities in AD revealed putative brain and AD-associated immunogenic markers.


Subject(s)
Aging/blood , Aging/immunology , Alzheimer Disease/blood , Alzheimer Disease/immunology , Brain/immunology , Clone Cells/immunology , Genes, T-Cell Receptor gamma , Receptors, Antigen, T-Cell, gamma-delta/genetics , Adult , Aged , Aged, 80 and over , Complementarity Determining Regions/genetics , Female , High-Throughput Nucleotide Sequencing , Humans , Male , Middle Aged , Pilot Projects , Receptors, Antigen, T-Cell, gamma-delta/blood , Receptors, Antigen, T-Cell, gamma-delta/immunology , Young Adult
5.
Am J Hematol ; 95(2): 151-155, 2020 02.
Article in English | MEDLINE | ID: mdl-31709579

ABSTRACT

The T Cell Project was the largest prospective trial to explore the incidence, treatment patterns, and outcomes for T cell lymphomas. The rare subtypes of T cell lymphomas, including hepatosplenic T cell lymphoma (HSTCL), enteropathy associated T cell lymphoma (EATL), and peripheral gamma delta T cell lymphomas (PGDTCLs) are poorly represented in most studies and there is little data regarding treatment patterns. We report results from 115 patients with hepatosplenic (n = 31), enteropathy associated (n = 65), and PGDTCLs (n = 19). While anthracycline regimens were most commonly used as first line therapy, response rates ranged from 20%-40% and were suboptimal for all groups. Autologous stem cell transplantation was performed as a consolidation in first remission in a small number of patients (33% of HSTCL, 7% of EATL, and 12% of PGDTCL), and four patients with HSTCL underwent allogeneic stem cell transplantation in first remission. The progression free survival at 3 years ranged from 28%-40% for these rare subtypes, and the overall survival at 3 years was most favorable for PGDTCL (70%). These data highlight the need for novel treatment approaches for rare subtypes of T cell lymphomas and for their inclusion in clinical trials.


Subject(s)
Enteropathy-Associated T-Cell Lymphoma , Hematopoietic Stem Cell Transplantation , Lymphoma, T-Cell, Peripheral , Neoplasm Proteins/blood , Receptors, Antigen, T-Cell, gamma-delta/blood , Adolescent , Adult , Aged , Aged, 80 and over , Disease-Free Survival , Enteropathy-Associated T-Cell Lymphoma/blood , Enteropathy-Associated T-Cell Lymphoma/mortality , Enteropathy-Associated T-Cell Lymphoma/therapy , Female , Humans , Incidence , Lymphoma, T-Cell, Peripheral/blood , Lymphoma, T-Cell, Peripheral/mortality , Lymphoma, T-Cell, Peripheral/therapy , Male , Middle Aged , Survival Rate , Transplantation, Autologous
6.
PLoS Pathog ; 15(4): e1007715, 2019 04.
Article in English | MEDLINE | ID: mdl-30998783

ABSTRACT

Hepatitis B virus (HBV) persists with global and virus-specific T-cell dysfunction, without T-cell based correlates of outcomes. To determine if γδT-cells are altered in HBV infection relative to clinical status, we examined the frequency, phenotype and function of peripheral blood Vδ1+ and Vδ2+γδT-cells by multi-parameter cytometry in a clinically diverse North American cohort of chronic hepatitis B (CHB), acute hepatitis B (AHB) and uninfected control subjects. We show that circulating γδT-cells were comprised predominantly of CD3hiCD4- Vδ2+γδT-cells with frequencies that were 2-3 fold higher among Asian than non-Asian Americans and inversely correlated with age, but without differences between CHB, AHB and control subjects. However, compared to control subjects, CHB was associated with increased TbethiEomesdim phenotype in Vδ2+γδT-cells whereas AHB was associated with increased TbethiEomesdim phenotype in Vδ1+γδT-cells, with significant correlations between Tbet/Eomes expression in γδT-cells with their expression of NK and T-cell activation and regulatory markers. As for effector functions, IFNγ/TNF responses to phosphoantigens or PMA/Ionomycin in Vδ2+γδT-cells were weaker in AHB but preserved in CHB, without significant differences for Vδ1+γδT-cells. Furthermore, early IFNγ/TNF responses in Vδ2+ γδT-cells to brief PMA/Ionomycin stimulation correlated inversely with serum ALT but not HBV DNA. Accordingly, IFNγ/TNF responses in Vδ2+γδT-cells were weaker in patients with CHB with hepatitis flare compared to those without hepatitis flares, and this functional deficit persisted beyond clinical resolution of CHB flare. We conclude that circulating γδT-cells show distinct activation and differentiatiation in acute and chronic HBV infection as part of lymphoid stress surveillance with potential role in clinical outcomes.


Subject(s)
Hepatitis B virus/immunology , Hepatitis B, Chronic/immunology , Lymphocyte Activation/immunology , Receptors, Antigen, T-Cell, gamma-delta/immunology , T-Lymphocytes/immunology , Adolescent , Adult , Aged , Biomarkers/analysis , Cohort Studies , Female , Hepatitis B, Chronic/blood , Hepatitis B, Chronic/virology , Humans , Male , Middle Aged , Phenotype , Receptors, Antigen, T-Cell, gamma-delta/blood , Young Adult
7.
Int J Mol Sci ; 20(3)2019 Feb 05.
Article in English | MEDLINE | ID: mdl-30764544

ABSTRACT

Pregnancy is a state where high and stage-dependent plasticity of the maternal immune system is necessary in order to equilibrate between immunosuppression of harmful responses towards the fetus and ability to fight infections. TCR γδ cells have been implicated in the responses in infectious diseases, in the regulation of immune responses, and in tissue homeostasis and repair. The variety of functions makes γδ T cells a particularly interesting population during pregnancy. In this study, we investigated the proportion, phenotype and TCR γ and δ repertoires of γδ T cells at the maternal⁻fetal interface and in the blood of pregnant women using FACS, immunohistochemistry and spectratyping. We found an enrichment of activated and terminally differentiated pro-inflammatory γδ T-cell effectors with specific location in the human decidua during early pregnancy, while no significant changes in their counterparts in the blood of pregnant women were observed. Our spectratyping data revealed polyclonal CDR3 repertoires of the δ1, δ2 and δ3 chains and γ2, γ3, γ4 and γ5 chains and oligoclonal and highly restricted CDR3γ9 repertoire of γδ T cells in the decidua and blood of pregnant women. Early pregnancy induces recruitment of differentiated pro-inflammatory γδ T-cell effectors with diverse TCR repertoires at the maternal⁻fetal interface.


Subject(s)
Decidua/immunology , Fetus/immunology , Receptors, Antigen, T-Cell, gamma-delta/immunology , T-Lymphocytes/immunology , Female , Humans , Immune Tolerance , Lymphocyte Activation , Pregnancy , Receptors, Antigen, T-Cell, gamma-delta/analysis , Receptors, Antigen, T-Cell, gamma-delta/blood
8.
Front Immunol ; 9: 2783, 2018.
Article in English | MEDLINE | ID: mdl-30568654

ABSTRACT

Even with effective viral control, HIV-infected individuals are at a higher risk for morbidities associated with older age than the general population, and these serious non-AIDS events (SNAEs) track with plasma inflammatory and coagulation markers. The cell subsets driving inflammation in aviremic HIV infection are not yet elucidated. Also, whether ART-suppressed HIV infection causes premature induction of the inflammatory events found in uninfected elderly or if a novel inflammatory network ensues when HIV and older age co-exist is unclear. In this study we measured combinational expression of five inhibitory receptors (IRs) on seven immune cell subsets and 16 plasma markers from peripheral blood mononuclear cells (PBMC) and plasma samples, respectively, from a HIV and Aging cohort comprised of ART-suppressed HIV-infected and uninfected controls stratified by age (≤35 or ≥50 years old). For data analysis, multiple multivariate computational algorithms [cluster identification, characterization, and regression (CITRUS), partial least squares regression (PLSR), and partial least squares-discriminant analysis (PLS-DA)] were used to determine if immune parameter disparities can distinguish the subject groups and to investigate if there is a cross-impact of aviremic HIV and age on immune signatures. IR expression on gamma delta (γδ) T cells exclusively separated HIV+ subjects from controls in CITRUS analyses and secretion of inflammatory cytokines and cytotoxic mediators from γδ T cells tracked with TIGIT expression among HIV+ subjects. Also, plasma markers predicted the percentages of TIGIT+ γδ T cells in subjects with and without HIV in PSLR models, and a PLS-DA model of γδ T cell IR signatures and plasma markers significantly stratified all four of the subject groups (uninfected younger, uninfected older, HIV+ younger, and HIV+ older). These data implicate γδ T cells as an inflammatory driver in ART-suppressed HIV infection and provide evidence of distinct "inflamm-aging" processes with and without ART-suppressed HIV infection.


Subject(s)
Aging , Algorithms , Anti-Retroviral Agents/administration & dosage , HIV Infections , HIV-1 , Intraepithelial Lymphocytes , Receptors, Antigen, T-Cell, gamma-delta , Adult , Aging/blood , Aging/immunology , Aging/pathology , Biomarkers/blood , HIV Infections/blood , HIV Infections/drug therapy , HIV Infections/immunology , HIV Infections/pathology , HIV-1/immunology , HIV-1/metabolism , Humans , Intraepithelial Lymphocytes/immunology , Intraepithelial Lymphocytes/metabolism , Intraepithelial Lymphocytes/pathology , Intraepithelial Lymphocytes/virology , Middle Aged , Models, Immunological , Receptors, Antigen, T-Cell, gamma-delta/blood , Receptors, Antigen, T-Cell, gamma-delta/immunology
9.
Shock ; 48(3): 321-328, 2017 09.
Article in English | MEDLINE | ID: mdl-28362715

ABSTRACT

INTRODUCTION: Recent studies demonstrated the significant loss of gamma delta T (γδ T) cells in patients with sepsis. Given the distinct functions of γδ T cells in human anti-infection immunity, we are interested in evaluating the phenotype and function of peripheral γδ T cells in septic patients and determining their prognostic implication. METHOD: This prospective study has been conducted in three intensive care units of a university hospital. During the period from October 2014 to June 2015, we enrolled 107 patients who were consecutively admitted and diagnosed with severe sepsis or septic shock (excluding previous immunosuppression) and 45 healthy controls. Using flow cytometry, we analyzed the in vivo percentage of γδ T cells in cluster of differentiation (CD)3 cells from peripheral blood mononuclear cells as well as their expression of surface markers (CD69, natural-killer group 2 member D [NKG2D], programmed death receptor 1 [PD-1]) and intracellular cytokines (interferon-γ [IFN-γ], interleukin [IL]-17, IL-10, transforming growth factor-ß [TGF-ß]). Then we further evaluated the different responses of γδ T cells after the antigen stimulation ex vivo by measuring CD69 and IFN-γ expression. Lastly, we conducted the multiple logistic regressions to analyze the risk factor for prognosis. RESULTS: Compared with control group, γδ T cells in septic patients displayed a decrease in percentage, increase in CD69, decrease in NKG2D, and increase in cytokine expression (pro-inflammatory IFN-γ, IL-17, anti-inflammatory IL-10, TGF-ß) in vivo. After the antigen stimulation ex vivo, both CD69 and IFN-γ expression in γδ T cells were significantly lower in septic patients than control group. Importantly, the decrease in CD69 and IFN-γ expression was more pronounced in non-survivors than survivors. Multiple logistic regression analysis revealed that lower expression of IFN-γ after stimulation is a dependent risk factor that associated with patient 28-day death in septic patients (OR: 0.908 [95% CI: 0.853-0.966]). CONCLUSION: Septic patients showed altered phenotype and function of γδ T cells. The impaired IFN-γ expression by γδ T cells after the antigen stimulation is associated with mortality in septic patients.


Subject(s)
Antigens, Differentiation/blood , Cytokines/blood , Receptors, Antigen, T-Cell, gamma-delta/blood , Sepsis/blood , T-Lymphocytes/metabolism , Adult , Aged , Female , Humans , Male , Middle Aged , Risk Factors , Sepsis/mortality , Sepsis/pathology , T-Lymphocytes/pathology
10.
Eur J Cancer ; 64: 116-26, 2016 09.
Article in English | MEDLINE | ID: mdl-27400322

ABSTRACT

Human γδ T-cells possess regulatory and cytotoxic capabilities, and could potentially influence the efficacy of immunotherapies. We analysed the frequencies of peripheral γδ T-cells, including their most prominent subsets (Vδ1+ and Vδ2+ cells) and differentiation states in 109 melanoma patients and 109 healthy controls. We additionally analysed the impact of γδ T-cells on overall survival (OS) calculated from the first dose of ipilimumab in melanoma patients. Higher median frequencies of Vδ1+ cells and lower median frequencies of Vδ2+ cells were identified in patients compared to healthy subjects (Vδ1+: 30% versus 15%, Vδ2+: 39% versus 64%, both p < 0.001). Patients with higher frequencies of Vδ1+ cells (≥30%) had poorer OS (p = 0.043) and a Vδ1+ differentiation signature dominated by late-differentiated phenotypes. In contrast, higher frequencies of Vδ2+ cells (≥39%) were associated with longer survival (p = 0.031) independent of the M category or lactate dehydrogenase level. Patients with decreasing frequencies of Vδ2+ cells under ipilimumab treatment had worse OS and a lower rate of clinical benefit than patients without such decreases. Therefore, we suggest frequencies of both Vδ1+ and Vδ2+ cells as candidate biomarkers for outcome in melanoma patients following ipilimumab. Further studies are needed to validate these results and to clarify whether they represent prognostic associations or whether γδ T-cells are specifically and/or functionally linked to the mode of action of ipilimumab.


Subject(s)
Antibodies, Monoclonal/therapeutic use , Antineoplastic Agents/therapeutic use , Biomarkers, Tumor/blood , Immunotherapy/methods , Melanoma/drug therapy , Melanoma/immunology , Receptors, Antigen, T-Cell, gamma-delta/blood , T-Lymphocyte Subsets/cytology , Adult , Aged , Aged, 80 and over , Case-Control Studies , Cell Differentiation , Female , Flow Cytometry , Humans , Ipilimumab , Male , Middle Aged , Prognosis , T-Lymphocyte Subsets/immunology
11.
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi ; 32(5): 671-5, 2016 May.
Article in Chinese | MEDLINE | ID: mdl-27126948

ABSTRACT

OBJECTIVE: To investigate the percentages and correlations of innate-like lymphocyte subsets, αßT cells and B2 cells in peripheral blood of patients with non-small cell lung cancer (NSCLC) and normal individuals. METHODS: A total of 16 healthy controls, 5 NSCLC first-visit patients and 15 NSCLC stable-state patients were included to take the peripheral blood samples. Flow cytometry was performed to detect the percentages of invariant natural killer T (iNKT), γδT, B1, αßT and B2 cell subsets in peripheral blood lymphocytes. RESULTS: The percentage of iNKT cells in the stable-state patients was significantly lower than that of the healthy people and first-visit patients. In addition, the percentage of αßT cells in the stable-state patients was significantly higher than that of the healthy people. The fist-visit patients had a markedly higher percentage of γδT cells than the stable-state patients, but a significantly lower percentage of B1 cells than the healthy people. There was an obviously positive correlation between iNKT cells and γδT cells in the stable-state patients. We also found a significantly positive correlation between B1 cells and B2 cells in both stable-state patients and healthy people. CONCLUSION: The percentages of innate-like lymphocyte subsets in patients with NSCLC are in disequilibrium.


Subject(s)
Carcinoma, Non-Small-Cell Lung/immunology , Lung Neoplasms/immunology , Lymphocyte Subsets/immunology , Adult , Aged , Female , Humans , Male , Middle Aged , Natural Killer T-Cells/immunology , Receptors, Antigen, T-Cell, alpha-beta/blood , Receptors, Antigen, T-Cell, gamma-delta/blood
12.
Asian Pac J Allergy Immunol ; 34(4): 300-305, 2016 Dec.
Article in English | MEDLINE | ID: mdl-27001659

ABSTRACT

BACKGROUND: Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME), and Multiple Sclerosis (MS) may share some similarities in relation to reduced NK cell activity. It is likely that other cells such as regulatory T (Tregs), invariant Natural Killer T (iNKT) and gamma delta T (γδ T) cells may also be dysregulated in CFS/ME and MS. OBJECTIVE: To evaluate and compare specific immune regulatory cells of patients with CFS/ME, patients with MS and healthy controls. METHOD: Sixty three volunteers were included in this study: 24 were CFS/ME patients, 11 were MS patients and 27 were healthy controls. Blood samples were obtained from all participants for flow cytometry analysis of iNKT cells, Tregs and γδ T cell phenotypes. RESULTS: We observed a significant increase in Tregs in the CFS/ME group (p≤0.05) compared to the healthy control group. Total γδ and γδ2 T cells were significantly reduced in MS patients in comparison with the healthy control group. Conversely, CD4+iNKT percentage of iNKT, was significantly increased in the CFS/ME group compared with healthy controls and the double-negative iNKT percentage of iNKT significantly decreased compared with the healthy control group. CONCLUSIONS: This study has not identified any immunological disturbances that are common in both MS and CFS/ME patients. However, the differential expression of cell types between the conditions investigated suggests different pathways of disease. These differences need to be explored in further studies.


Subject(s)
Fatigue Syndrome, Chronic/immunology , Multiple Sclerosis/immunology , Natural Killer T-Cells/immunology , T-Lymphocyte Subsets/immunology , T-Lymphocytes, Regulatory/immunology , Adult , Cell Separation , Fatigue Syndrome, Chronic/blood , Female , Flow Cytometry , Humans , Immunophenotyping , Male , Middle Aged , Multiple Sclerosis/blood , Receptors, Antigen, T-Cell, gamma-delta/blood , Receptors, Antigen, T-Cell, gamma-delta/immunology
13.
Int J Rheum Dis ; 19(6): 586-93, 2016 Jun.
Article in English | MEDLINE | ID: mdl-24467668

ABSTRACT

AIM: γδ T cells exhibit important functions in the pathogenesis of rheumatoid arthritis (RA). In recent years, numerous studies harnessed the γδ T cell-activating capacity of aminobiphosphonates for the treatment of malignant tumors. As (99) Tc-methylene diphosphonate ((99) Tc-MDP) has long been widely used for the treatment of RA in China with good efficacy, we are interested in whether this drug exerts its therapeutic effect on RA by modulating peripheral γδ T cells of RA patients. OBJECTIVES: To investigate the effect of (99) Tc-MDP on the frequency of γδ T cells and CD4(+) CD25(+) Foxp3(+) Tregs in the peripheral blood of patients with active RA. METHODS: Nineteen patients with active RA were treated with (99) Tc-MDP intravenously at a dose of 20 µg/day consecutively for 10-14 days. Before and after treatment, the main clinical and laboratory parameters for each patient were evaluated. The frequency of CD3(+) γδ(+) T cells and CD4(+) CD25(+) Foxp3(+) Tregs was detected by flow cytometry. Serum levels of interferon (IFN)-γ, tumor necrosis factor (TNF)-α, interleukin (IL)-6, IL-10 and transforming growth factor (TGF)-ß were measured with enzyme-linked immunosorbent assay. RESULTS: After intravenous (99) Tc-MDP therapy, the frequency of peripheral CD3(+) γδ(+) T cells and CD4(+) CD25(+) Foxp3(+) Tregs were significantly elevated, paralleled with decreased serum levels of TNF-α and IL-6 and increased level of serum TGF-ß. The elevation of peripheral CD3(+) γδ(+) T cells was positively correlated with increased serum TGF-ß and decreased disease activity. CONCLUSION: (99) Tc-MDP may improve the activity of RA through upregulating the frequency of peripheral γδ T cells and CD4(+) CD25(+) Foxp3(+) Tregs as well as affecting the serum cytokine environment by increasing TGF-ß and decreasing TNF-α and IL-6.


Subject(s)
Arthritis, Rheumatoid/radiotherapy , Forkhead Transcription Factors/immunology , Interleukin-2 Receptor alpha Subunit/immunology , Radiopharmaceuticals/therapeutic use , Receptors, Antigen, T-Cell, gamma-delta/immunology , T-Lymphocytes, Regulatory/radiation effects , Technetium Tc 99m Medronate/therapeutic use , Administration, Intravenous , Aged , Arthritis, Rheumatoid/blood , Arthritis, Rheumatoid/diagnostic imaging , Arthritis, Rheumatoid/immunology , Case-Control Studies , Cytokines/blood , Cytokines/immunology , Drug Administration Schedule , Female , Forkhead Transcription Factors/blood , Humans , Interleukin-2 Receptor alpha Subunit/blood , Male , Middle Aged , Phenotype , Radiopharmaceuticals/administration & dosage , Radiopharmaceuticals/adverse effects , Receptors, Antigen, T-Cell, gamma-delta/blood , T-Lymphocytes, Regulatory/immunology , T-Lymphocytes, Regulatory/metabolism , Technetium Tc 99m Medronate/administration & dosage , Technetium Tc 99m Medronate/adverse effects , Time Factors , Treatment Outcome
14.
Int J Hematol ; 102(4): 426-33, 2015 Oct.
Article in English | MEDLINE | ID: mdl-26267232

ABSTRACT

Dasatinib, a 2nd-generation tyrosine kinase inhibitor (TKI), can specifically induce large granular lymphocytes (LGL) in some patients with Philadelphia chromosome (Ph)-positive leukemia. To investigate the properties of the induced LGLs, we performed prospective and longitudinal analyses. From Feb 2011 to Jan 2013, a total of 17 patients with Ph-positive leukemia who were previously untreated or refractory to imatinib were enrolled. T cell receptor (TCR)-γ/δ gene rearrangements and phenotypic profiles of lymphocytes were examined before and during administration of dasatinib. LGL lymphocytosis was observed in half of the dasatinib-treated cases (LGL+ group), showing a relation to increased achievement of complete cytogenetic response within 6 months. The phenotypes of the increased lymphocytes were revealed to be mostly natural killer cells. In the LGL+ group, clonal TCR-γ gene rearrangements were frequently detected at diagnosis (six of nine cases) and persisted during therapy, compared with only two of eight in the LGL- group. The proportion of regulatory T cells to CD4+ T cells at diagnosis was lower in the LGL+ compared with the LGL- group (median 4.2 vs. 6.6 %), and this disparity was sustained throughout the therapeutic period. These results demonstrate that immunological condition at diagnosis may affect LGL lymphocytosis in some dasatinib-treated patients.


Subject(s)
CD4-Positive T-Lymphocytes , Dasatinib/administration & dosage , Gene Rearrangement, delta-Chain T-Cell Antigen Receptor , Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor , Leukemia, Large Granular Lymphocytic , Precursor Cell Lymphoblastic Leukemia-Lymphoma , Receptors, Antigen, T-Cell, gamma-delta , Adult , Aged , Female , Follow-Up Studies , Humans , Killer Cells, Natural/metabolism , Leukemia, Large Granular Lymphocytic/blood , Leukemia, Large Granular Lymphocytic/drug therapy , Leukemia, Large Granular Lymphocytic/genetics , Male , Middle Aged , Precursor Cell Lymphoblastic Leukemia-Lymphoma/blood , Precursor Cell Lymphoblastic Leukemia-Lymphoma/drug therapy , Precursor Cell Lymphoblastic Leukemia-Lymphoma/genetics , Receptors, Antigen, T-Cell, gamma-delta/blood , Receptors, Antigen, T-Cell, gamma-delta/genetics
15.
Int J Hematol ; 102(4): 498-505, 2015 Oct.
Article in English | MEDLINE | ID: mdl-25975265

ABSTRACT

Peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS), frequently shows a poor outcome. Especially, expressions of CC chemokine receptor 4 (CCR4) and γδ T-cell receptor (TCR) are associated with worse prognosis in PTCL-NOS. We here report successful treatment with autologous peripheral blood stem cell transplantation (auto-PBSCT) combined with anti-CCR4 antibody mogamulizumab for a very rare case of CCR4+γδTCR+ PTCL-NOS that coexisted with Hodgkin's lymphoma. PTCL-NOS in this patient progressed to leukemic phase, whereas Hodgkin's lymphoma disappeared with standard chemotherapies within 4 years of the initial diagnosis. Leukemic-phase PTCL-NOS was refractory to several chemotherapies. However, auto-PBSCT following high-dose chemotherapy combined with pre- and post-transplant mogamulizumab, which is a humanized monoclonal antibody to CCR4, provided persistent complete remission of PTCL-NOS, despite residual γδTCR+ in the transplanted stem cell product, suggesting a purging effect of mogamulizumab. At 15 months after transplantation, we also found markedly fewer effector regulatory T cells, which may have contributed to prolonged remission. This case suggests that autologous stem cell transplantation combined with mogamulizumab may have a potential to cure T-cell neoplasms that express CCR4 including leukemic-phase PTCL-NOS.


Subject(s)
Antibodies, Monoclonal, Humanized/administration & dosage , Precursor T-Cell Lymphoblastic Leukemia-Lymphoma , Receptors, Antigen, T-Cell, gamma-delta/blood , Receptors, CCR4/antagonists & inhibitors , Stem Cell Transplantation , Autografts , Humans , Male , Middle Aged , Precursor T-Cell Lymphoblastic Leukemia-Lymphoma/blood , Precursor T-Cell Lymphoblastic Leukemia-Lymphoma/therapy , Receptors, CCR4/blood , Remission Induction
16.
Vet Clin Pathol ; 44(3): 442-7, 2015 Sep.
Article in English | MEDLINE | ID: mdl-25965815

ABSTRACT

A 2-year and 6-month-old female neutered Labrador Retriever with Horner syndrome, megaesophagus, and a mediastinal mass was referred to the Queen Mother Hospital for Animals of the Royal Veterinary College. A large granular lymphocyte (LGL) lymphoma was diagnosed on cytology; flow cytometric analysis revealed a γδ T-cell phenotype (CD3+, CD5+, CD45+, TCRγδ+, CD4-, CD8-, CD34-, CD21-). Chemotherapy was started with a combination of lomustine, vincristine, procarbazine, and prednisolone, followed by bleyomicin. Euthanasia was elected by the owners, due to progressive deterioration and lack of quality of life, 28 days after diagnosis. This is the first cytologic and immunophenotypic characterization of a canine γδ T-cell lymphoma with LGL morphology and probably of mediastinal origin. The role of chemotherapy in delaying the disease progression remains unknown.


Subject(s)
Dog Diseases/pathology , Lymphoma, T-Cell/veterinary , Receptors, Antigen, T-Cell, gamma-delta/blood , Animals , Antineoplastic Agents/therapeutic use , Dog Diseases/drug therapy , Dogs , Euthanasia, Animal , Female , Flow Cytometry/veterinary , Immunophenotyping/veterinary , Lymphoma, T-Cell/drug therapy , Lymphoma, T-Cell/pathology , Quality of Life , T-Lymphocytes/pathology
17.
PLoS One ; 10(5): e0122387, 2015.
Article in English | MEDLINE | ID: mdl-25955158

ABSTRACT

Human γδ T cells are potent effectors against glioma cell lines in vitro and in human/mouse xenograft models of glioblastoma, however, this effect has not been investigated in an immunocompetent mouse model. In this report, we established GL261 intracranial gliomas in syngeneic WT C57BL/6 mice and measured circulating γδ T cell count, phenotype, Vγ/Vδ repertoire, tumor histopathology, NKG2D ligands expression, and T cell invasion at day 10-12 post-injection and at end stage. Circulating γδ T cells transiently increased and upregulated Annexin V expression at post-tumor day 10-12 followed by a dramatic decline in γδ T cell count at end stage. T cell receptor repertoire showed no changes in Vγ1, Vγ4, Vγ7 or Vδ1 subsets from controls at post-tumor day 10-12 or at end stage except for an end-stage increase in the Vδ4 population. Approximately 12% of γδ T cells produced IFN-γ. IL-17 and IL-4 producing γδ T cells were not detected. Tumor progression was the same in TCRδ-/- C57BL/6 mice as that observed in WT mice, suggesting that γδ T cells exerted neither a regulatory nor a sustainable cytotoxic effect on the tumor. WT mice that received an intracranial injection of γδ T cells 15m following tumor placement showed evidence of local tumor growth inhibition but this was insufficient to confer a survival advantage over untreated controls. Taken together, our findings suggest that an early nonspecific proliferation of γδ T cells followed by their depletion occurs in mice implanted with syngeneic GL261 gliomas. The mechanism by which γδ T cell expansion occurs remains a subject for further investigation of the mechanisms responsible for this immune response in the setting of high-grade glioma.


Subject(s)
Brain Neoplasms/immunology , Brain Neoplasms/pathology , Brain/metabolism , Glioma/immunology , Glioma/pathology , Receptors, Antigen, T-Cell, gamma-delta/immunology , T-Lymphocyte Subsets/immunology , Animals , Brain/immunology , Brain Neoplasms/blood , Cell Line, Tumor , Disease Models, Animal , Glioma/blood , Humans , Interleukin-17/immunology , Interleukin-4/immunology , Mice, Inbred C57BL , Receptors, Antigen, T-Cell, gamma-delta/analysis , Receptors, Antigen, T-Cell, gamma-delta/blood , T-Lymphocyte Subsets/pathology
18.
Asian Pac J Allergy Immunol ; 32(3): 235-9, 2014 Sep.
Article in English | MEDLINE | ID: mdl-25268341

ABSTRACT

BACKGROUD: Gammadelta-T-cells play an important role in the mucosal immune system of the respiratory tract. Th17 cells plays an important role in promoting inflammation and autoimmune diseases. Th17 cells mainly secrete IL-17. However, little information is available on the relation between gammadelta-T-cells and Th17 cells in allergic rhinitis (AR). OBJECTIVE: To explore the correlation between the prevalence of gammadelta-T-cells, the prevalence of Th17 cells and the expression of IL-17 in the peripheral blood of patients with AR. METHODS: Peripheral blood from the AR group (32 cases) and the control group (20 cases) was collected from March 2012 to July 2012. The percentages of gammadelta-T-cells and Th17 cells were measured by flow cytometry, and the levels of IL-17 were measured by ELISA. RESULTS: The percentage of gammadeta-T-cells and Th17 cells in the AR group were significantly higher than those in the control group (P < 0.01). The levels of IL-17 in the AR group were also significantly higher than those in the control group (P < 0.01). There were positive correlations between the gammadelta-T-cell percentage and the Th17 cell percentage in the peripheral blood of AR patients (r = 0.597, P < 0.01); and between the gammadelta-T-cells percentage and the levels of IL-17 (r = 0.469,P < 0.01). However, no correlation was found between the Th17 cell percentage and the levels of IL-17 (r = 0.100, P > 0.05). CONCLUSION: Gammadelta-T-cells and Th17 cells may be involved in the pathogenesis of AR; gammadelta-T-cells may primarily be associated with the secretion of IL-17.


Subject(s)
Interleukin-17/blood , Receptors, Antigen, T-Cell, gamma-delta/blood , Rhinitis, Allergic/blood , Th17 Cells/metabolism , Adolescent , Adult , Female , Humans , Male , Middle Aged , Rhinitis, Allergic/pathology , Th17 Cells/pathology
19.
Asian Pac J Allergy Immunol ; 32(3): 261-9, 2014 Sep.
Article in English | MEDLINE | ID: mdl-25268345

ABSTRACT

BACKGROUND: Infection is one of the most common causes of death in ß-thalassemia patients. This may be due in part to an underlying immunological abnormality. During the past decade, a subset of CD3+ T cells that express both CD4+CD8+ (DP) T-cells were discovered and have been described in several pathological conditions. However, phenotypic characterization of this unique T-lymphocyte subset in patients with ß-thalassemia has not yet been investigated. METHODS: Flow cytometry was used to determine the frequency of such CD4+CD8+(DP) cells in concert with frequencies of CD4+, CD8+, NKT cells and γδ-TCR T-lymphocytes in the peripheral blood of ß-thalassemia/HbE patients. The frequencies of these lymphocyte subsets were compared with those in blood samples from healthy volunteers. RESULTS: The results showed that the frequency of lymphocytes was significantly increased in splenectomized ß-thalassemia/HbE patients but the frequencies of CD3+, CD4+ and CD8+ T-lymphocytes were not significantly different among the studied groups. However, analysis of unconventional T-lymphocytes revealed a significant increase in the frequency of CD4-CD8- in splenectomized ß-thalassemia/HbE patients. The frequencies of CD4-CD8dim and CD4+CD8+ in ß-thalassemia/HbE patients were similar to the controls. Further classification of the CD4+CD8+ cells revealed that ß-thalassemia/HbE patient expressed significantly high levels of CD4brightCD8dim, with a marked increase found in non-splenectomized patients. Furthermore, significant increases in the frequency of γδ-TCR and NKT cells were also demonstrated in these splenectomized ß-thalassemia/HbE patients. CONCLUSION: Our findings show the alteration of unconventional T-lymphocyte subsets in ß-thalassemia/HbE patients, which may be responsible or may reflect the impaired immune response in ß-thalssemia disease.


Subject(s)
CD4-Positive T-Lymphocytes/metabolism , CD8-Positive T-Lymphocytes/metabolism , Receptors, Antigen, T-Cell, gamma-delta/blood , beta-Thalassemia/blood , CD4-Positive T-Lymphocytes/immunology , CD4-Positive T-Lymphocytes/pathology , CD8-Positive T-Lymphocytes/immunology , CD8-Positive T-Lymphocytes/pathology , Female , Humans , Male , Natural Killer T-Cells/immunology , Natural Killer T-Cells/metabolism , Receptors, Antigen, T-Cell, gamma-delta/immunology , beta-Thalassemia/immunology , beta-Thalassemia/pathology
20.
Mol Ther ; 22(8): 1416-1422, 2014 Aug.
Article in English | MEDLINE | ID: mdl-24895997

ABSTRACT

Exploration of cancer immunotherapy strategies that incorporate γδ T cells as primary mediators of antitumor immunity are just beginning to be explored and with a primary focus on the use of manufactured phosphoantigen-stimulated Vγ9Vδ2 T cells. Increasing evidence, however, supports a critical role for Vδ1+ γδ T cells, a minor subset in peripheral blood with distinct innate recognition properties that possess powerful tumoricidal activity. They are activated by a host of ligands including stress-induced self-antigens, glycolipids presented by CD1c/d, and potentially many others that currently remain unidentified. In contrast to Vγ9Vδ2 T cells, tumor-reactive Vδ1+ T cells are not as susceptible to activation-induced cell death and can persist in the circulation for many years, potentially offering durable immunity to some cancers. In addition, specific populations of Vδ1+ T cells can also exhibit immunosuppressive and regulatory properties, a function that can also be exploited for therapeutic purposes. This review explores the biology, function, manufacturing strategies, and potential therapeutic role of Vδ1+ T cells. We also discuss clinical experience with Vδ1+ T cells in the setting of cancer, as well as the potential of and barriers to the development of Vδ1+ T cell-based adoptive cell therapy strategies.


Subject(s)
Cell- and Tissue-Based Therapy/methods , Receptors, Antigen, T-Cell, gamma-delta/metabolism , T-Lymphocytes/cytology , Humans , Neoplasms/therapy , Receptors, Antigen, T-Cell, gamma-delta/blood
SELECTION OF CITATIONS
SEARCH DETAIL